Arbutus Biopharma

ABUS

Valor de mercado US$ 836 mi

Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could generate $1.59–$2.39B in peak annual revenue if successful. Current valuation ($4.50/share) slightly exceeds risk-adjusted fair value ($3.91), with upside tied to positive Phase 2b/3 Imdusiran results.

WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and included the option for shareholders to participate via a proportionate tender. The Offer expired at 5:00 p.m. (New York City time) on September 29, 2026. All amounts are in U.S. dollars.

WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the preliminary results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and included the option for shareholders to participate via a proportionate tender. The Offer expired at 5:00 p.m. (New York City time) on September 29, 2026. All amounts are in U.S. dollars.

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without interest, on the terms and subject to the conditions described in the offer to purchase and accompanying issuer bid circular, dated August 24, 2026 (the “Offer to Purchase and Bid Circular”), the Letter of Transmittal (the “Letter of Transmittal”) and Notice of Guaranteed Delivery (the “Notice of Guaranteed Delivery”) (which together, as they may be amended and supplemented from time to time, constitute the “Offer”).

WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified “Dutch Auction” tender offer (the “Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire on or about September 29, 2026. The Offer is expected to be funded through the Company's cash on hand.

Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech

Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B (“cHBV”).